[Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
Twenty-seven patients with systemic scleroderma and Raynaud's phenomenon underwent a randomised double blind therapeutic trial: monotherapy with Ketanserine (80 mg/day for 6 months) against Placebo. The secondary effects were comparable in both groups as were the withdrawals from the trial for aggravation of Raynaud's phenomenon (one in each group). No significant difference was observed between the two groups as regards the evolution of the Raynaud's phenomenon or skin changes. Dysphagia was improved in the Ketanserine group (p less than 0.05) but not in the Placebo group. Some patients in the Ketanserine group experienced an improvement in the Raynaud's phenomenon at the end of the trial period; there were no improvements in the Placebo group. Three haemorrheological parameters (total blood viscosity, plasma viscosity and thixotropism) were abnormal at the beginning of the trial and did not improve by the end in the Ketanserine group. The K infinity coefficient of Quemada's law was normal at the start of the trial and increased after treatment (p less than 0.05).
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy; D012212:Rheology; D012595:Scleroderma, Systemic / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
D007650:Ketanserin
Traitement de la sclérodermie systémique par la Kétansérine. Etude randomisée, en double aveugle, sur 6 mois, de 27 cas.